SG11201408052WA - IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS - Google Patents
IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORSInfo
- Publication number
- SG11201408052WA SG11201408052WA SG11201408052WA SG11201408052WA SG11201408052WA SG 11201408052W A SG11201408052W A SG 11201408052WA SG 11201408052W A SG11201408052W A SG 11201408052WA SG 11201408052W A SG11201408052W A SG 11201408052WA SG 11201408052W A SG11201408052W A SG 11201408052WA
- Authority
- SG
- Singapore
- Prior art keywords
- imidazo
- compound
- kinase inhibitors
- pyridazine derivatives
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
Abstract
- 285 - Abstract The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R , G, T, Y , Y , Y , and Y are as defined 1 1 2 3 4 herein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012127079 | 2012-06-04 | ||
PCT/JP2013/065328 WO2013183578A1 (en) | 2012-06-04 | 2013-06-03 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVE AS KINASE INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408052WA true SG11201408052WA (en) | 2015-01-29 |
Family
ID=49711970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408052WA SG11201408052WA (en) | 2012-06-04 | 2013-06-03 | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS |
Country Status (32)
Country | Link |
---|---|
US (2) | US9187489B2 (en) |
EP (1) | EP2857404B1 (en) |
JP (1) | JP5814467B2 (en) |
KR (1) | KR101781255B1 (en) |
CN (1) | CN104520300B (en) |
AU (1) | AU2013272701B2 (en) |
BR (1) | BR112014029851B1 (en) |
CA (1) | CA2874819C (en) |
CO (1) | CO7160119A2 (en) |
CY (1) | CY1119607T1 (en) |
DK (1) | DK2857404T3 (en) |
ES (1) | ES2648228T3 (en) |
HK (1) | HK1207374A1 (en) |
HR (1) | HRP20171724T1 (en) |
HU (1) | HUE037221T2 (en) |
IL (1) | IL236075A (en) |
IN (1) | IN2014MN02497A (en) |
LT (1) | LT2857404T (en) |
MX (1) | MX357021B (en) |
MY (1) | MY170326A (en) |
NO (1) | NO2857404T3 (en) |
NZ (1) | NZ702574A (en) |
PH (1) | PH12014502721B1 (en) |
PL (1) | PL2857404T3 (en) |
PT (1) | PT2857404T (en) |
RS (1) | RS56625B1 (en) |
RU (1) | RU2635917C2 (en) |
SG (1) | SG11201408052WA (en) |
SI (1) | SI2857404T1 (en) |
TW (1) | TWI585088B (en) |
WO (1) | WO2013183578A1 (en) |
ZA (1) | ZA201408843B (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5503655B2 (en) | 2008-09-22 | 2014-05-28 | アレイ バイオファーマ、インコーポレイテッド | Substituted imidazo [1,2B] pyridazine compounds as TRK kinase inhibitors |
KR101784798B1 (en) | 2008-10-22 | 2017-10-16 | 어레이 바이오파마 인크. | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
AR077468A1 (en) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS |
WO2011146336A1 (en) | 2010-05-20 | 2011-11-24 | Array Biopharma Inc. | Macrocyclic compounds as trk kinase inhibitors |
CA2872645A1 (en) | 2012-05-30 | 2013-12-05 | Nippon Shinyaku Co., Ltd. | Aromatic heterocyclic derivative and pharmaceutical |
EA032255B1 (en) * | 2014-03-27 | 2019-04-30 | Янссен Фармацевтика Нв | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-α]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-α][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS |
CA2941206C (en) * | 2014-03-27 | 2022-09-20 | Janssen Pharmaceutica Nv | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine derivatives and 2,3-dihydro-1h-imidazo[1,2-b]pyrazole derivatives as ros1 inhibitors |
MX2016013600A (en) * | 2014-04-25 | 2017-04-27 | Exelixis Inc | Method of treating lung adenocarcinoma. |
RS64122B1 (en) | 2014-11-16 | 2023-05-31 | Array Biopharma Inc | Crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
EP3303631A1 (en) | 2015-06-01 | 2018-04-11 | Loxo Oncology Inc. | Methods of diagnosing and treating cancer |
MX2017016669A (en) | 2015-06-18 | 2018-04-13 | Cephalon Inc | 1, 4-substituted piperidine derivatives. |
US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
TN2018000027A1 (en) | 2015-07-16 | 2019-07-08 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
BR112018008357A2 (en) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | dot mutations in trk inhibitor resistant cancer and related methods |
CN106854174A (en) * | 2015-12-08 | 2017-06-16 | 湖南华腾制药有限公司 | A kind of preparation method of 4 substituted piperidine derivatives |
CR20180501A (en) | 2016-04-04 | 2019-04-05 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
KR20180129911A (en) | 2016-04-04 | 2018-12-05 | 록쏘 온콜로지, 인코포레이티드 | How to treat pediatric cancer |
PT3800189T (en) | 2016-05-18 | 2023-07-27 | Array Biopharma Inc | Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
CN107400082A (en) * | 2016-05-19 | 2017-11-28 | 湖南华腾制药有限公司 | A kind of preparation method of substituted piperidine derivative |
TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (en) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190072A1 (en) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | 1,3 di-substituted cyclobutane or azetidine derivatives as hematopoietic prostaglandin d synthase inhibitors |
JOP20190092A1 (en) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF |
CN110267960B (en) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
EP3597648B1 (en) | 2017-03-14 | 2023-06-07 | Daiichi Sankyo Company, Limited | METHOD FOR PRODUCING 3, 6-DISUBSTITUTED IMIDAZO[1, 2-b]PYRIDAZINE DERIVATIVE |
JOP20190213A1 (en) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | Macrocyclic compounds as ros1 kinase inhibitors |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
TWI791053B (en) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
TWI812649B (en) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
CN109748902B (en) * | 2017-11-02 | 2020-11-06 | 杭州科巢生物科技有限公司 | Preparation method of erlotinib hydrochloride |
US20230242670A1 (en) * | 2017-11-29 | 2023-08-03 | Seoul National University R&Db Foundation | Anti-ros1 antibody and use thereof |
CN108129288B (en) * | 2017-12-27 | 2021-01-22 | 上海毕得医药科技股份有限公司 | Synthesis method of trans-3-hydroxycyclobutylformic acid |
TW201938169A (en) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[3,4-d]pyrimidine compounds as RET kinase inhibitors |
CN111615514B (en) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors |
WO2019143977A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
EP3773725A1 (en) | 2018-03-29 | 2021-02-17 | Loxo Oncology Inc. | Treatment of trk-associated cancers |
JP7286755B2 (en) | 2018-07-31 | 2023-06-05 | ロクソ オンコロジー, インコーポレイテッド | (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole - Spray-dried dispersions and formulations of 4-carboxamides |
ES2922314T3 (en) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Fused Heterocyclic Compounds as RET Kinase Inhibitors |
CN113490666A (en) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | Substituted pyrazolo [1,5-A ] pyridine compounds as inhibitors of FGFR tyrosine kinases |
WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
TW202100526A (en) * | 2019-03-06 | 2021-01-01 | 日商第一三共股份有限公司 | Pyrrolopyrazole derivative |
CN114364798A (en) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | Combination of Dbait molecules with kinase inhibitors for the treatment of cancer |
CA3142088C (en) * | 2019-05-08 | 2023-02-28 | Tyk Medicines, Inc. | Compound used as kinase inhibitor and application thereof |
CN114761006A (en) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | Methods of treating cancer resistant to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
AR122159A1 (en) * | 2020-05-28 | 2022-08-17 | Novartis Ag | MLL1 INHIBITORS AND ANTINEOPLASTIC AGENTS |
CN114957259A (en) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | Cyano-substituted aromatic bicyclic compound and application thereof |
WO2023272701A1 (en) * | 2021-07-01 | 2023-01-05 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Crystalline forms of 3-{4-[(2r)-2-aminopropoxy]phenyl}-n-[(1r)- 1-(3-fluorophenyl) ethyl]imidazo[1,2-b]pyridazin-6-amine and salts thereof |
WO2023220967A1 (en) * | 2022-05-18 | 2023-11-23 | Anheart Therapeutics (Hangzhou) Co., Ltd. | Method for producing 3,6-disubstituted-imidazo[1,2-b]pyridazine compounds |
CN114989176A (en) * | 2022-07-08 | 2022-09-02 | 深圳市新樾生物科技有限公司 | Imidazopyridazine derivative and application thereof |
CN115197115A (en) * | 2022-08-25 | 2022-10-18 | 成都金博汇康医药科技有限公司 | Preparation method and application of chiral 5-oxopyrrolidine-3-formic acid |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399780B1 (en) | 1999-08-20 | 2002-06-04 | Cephalon, Inc. | Isomeric fused pyrrolocarbazoles and isoindolones |
EP1317446A1 (en) | 2000-09-01 | 2003-06-11 | Glaxo Group Limited | Oxindole derivatives |
EP1339680A1 (en) | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
JP2003231687A (en) | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | Pyrazolyl condensed ring compound and pharmaceutical use thereof |
MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
WO2005103010A2 (en) | 2004-04-21 | 2005-11-03 | Astrazeneca Ab | Pyrazole derivatives useful for the treatment of cancer |
EP1832588A4 (en) | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | Condensed imidazole compound and use thereof |
KR101302945B1 (en) | 2005-02-04 | 2013-09-06 | 아스트라제네카 아베 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors |
SI1853588T1 (en) | 2005-02-16 | 2008-10-31 | Astrazeneca Ab | Chemical compounds |
MX2007009842A (en) | 2005-02-16 | 2007-08-23 | Astrazeneca Ab | Chemical compounds. |
WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
WO2007014707A1 (en) * | 2005-08-01 | 2007-02-08 | F. Hoffmann-La Roche Ag | Heterocyclic benzylamino derivatives, their manufacture and use as pharmaceutical agents |
DE102005042742A1 (en) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituted imidazo [1,2b] pyridazines as kinase inhibitors, their production and use as pharmaceuticals |
DE102006029447A1 (en) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituted imidazo [1,2b] pyridazines, their preparation and use as pharmaceuticals |
AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
BRPI0718029A2 (en) * | 2006-11-06 | 2013-11-26 | Supergen Inc | IMIDAZO (1,2-B) PYRIDAZINE AND PIRAZOLE (1,5-A) PYRIMIDINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS |
WO2008072682A1 (en) * | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | Imidazo[1,2-b]pyridazine derivative |
JP2009227599A (en) * | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | Imidazopyridazine derivative |
WO2009140128A2 (en) | 2008-05-13 | 2009-11-19 | Irm Llc | Compounds and compositions as kinase inhibitors |
JP5503655B2 (en) * | 2008-09-22 | 2014-05-28 | アレイ バイオファーマ、インコーポレイテッド | Substituted imidazo [1,2B] pyridazine compounds as TRK kinase inhibitors |
KR101147550B1 (en) * | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 2,7-Substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors |
WO2012005299A1 (en) | 2010-07-07 | 2012-01-12 | 日本新薬株式会社 | Ros tyrosine kinase inhibitor |
WO2012125667A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
-
2013
- 2013-05-31 TW TW102119261A patent/TWI585088B/en active
- 2013-06-03 SG SG11201408052WA patent/SG11201408052WA/en unknown
- 2013-06-03 ES ES13801320.6T patent/ES2648228T3/en active Active
- 2013-06-03 JP JP2014519977A patent/JP5814467B2/en active Active
- 2013-06-03 RU RU2014153627A patent/RU2635917C2/en active
- 2013-06-03 WO PCT/JP2013/065328 patent/WO2013183578A1/en active Application Filing
- 2013-06-03 LT LTEP13801320.6T patent/LT2857404T/en unknown
- 2013-06-03 US US14/378,318 patent/US9187489B2/en active Active
- 2013-06-03 RS RS20171198A patent/RS56625B1/en unknown
- 2013-06-03 KR KR1020147033351A patent/KR101781255B1/en active IP Right Grant
- 2013-06-03 AU AU2013272701A patent/AU2013272701B2/en active Active
- 2013-06-03 MX MX2014014803A patent/MX357021B/en active IP Right Grant
- 2013-06-03 EP EP13801320.6A patent/EP2857404B1/en active Active
- 2013-06-03 CN CN201380041498.XA patent/CN104520300B/en active Active
- 2013-06-03 NO NO13801320A patent/NO2857404T3/no unknown
- 2013-06-03 PT PT138013206T patent/PT2857404T/en unknown
- 2013-06-03 CA CA2874819A patent/CA2874819C/en active Active
- 2013-06-03 DK DK13801320.6T patent/DK2857404T3/en active
- 2013-06-03 BR BR112014029851-3A patent/BR112014029851B1/en active IP Right Grant
- 2013-06-03 IN IN2497MUN2014 patent/IN2014MN02497A/en unknown
- 2013-06-03 HU HUE13801320A patent/HUE037221T2/en unknown
- 2013-06-03 PL PL13801320T patent/PL2857404T3/en unknown
- 2013-06-03 MY MYPI2014003346A patent/MY170326A/en unknown
- 2013-06-03 SI SI201330798T patent/SI2857404T1/en unknown
- 2013-06-03 NZ NZ702574A patent/NZ702574A/en unknown
-
2014
- 2014-12-02 ZA ZA2014/08843A patent/ZA201408843B/en unknown
- 2014-12-04 PH PH12014502721A patent/PH12014502721B1/en unknown
- 2014-12-04 IL IL236075A patent/IL236075A/en active IP Right Grant
- 2014-12-30 CO CO14286593A patent/CO7160119A2/en unknown
-
2015
- 2015-08-19 HK HK15108047.9A patent/HK1207374A1/en unknown
- 2015-10-29 US US14/926,973 patent/US9751887B2/en active Active
-
2017
- 2017-11-10 HR HRP20171724TT patent/HRP20171724T1/en unknown
- 2017-11-15 CY CY20171101204T patent/CY1119607T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408052WA (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS | |
TN2014000128A1 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
MD4556C1 (en) | Catechol O-methyltransferase activity inhibiting compounds | |
PH12015500064A1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
WO2012016186A8 (en) | Macrocyclic kinase inhibitors and uses thereof | |
MX2019003143A (en) | Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use thereof. | |
EP4275756A3 (en) | Bipyrazole derivatives as jak inhibitors | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
MY172924A (en) | Neprilysin inhibitors | |
MX2013004733A (en) | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS. | |
BR112012019765A2 (en) | compound, and use of a compound. | |
WO2014033447A3 (en) | Diaryl urea derivatives as p38 map kinase inhibitors | |
MX2017015277A (en) | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF. | |
JO3115B1 (en) | Pyridazinone Compounds and Their Use as DAAO Inhibitors | |
MX348860B (en) | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors. | |
MY184858A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
GEP20166481B (en) | (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors | |
MX340574B (en) | Imidazo pyrazines. | |
IN2015MN00002A (en) | ||
MX2012002327A (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy. | |
MX2013007937A (en) | Novel indole or indazole derivative or salt thereof. | |
TH148833B (en) | The imidazo derivative [1,2-b] piridazine is a kinase inhibitor. |